Northern Trust
FULC icon

Northern Trust’s Fulcrum Therapeutics FULC Stock Holding History

Northern Trust’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.79M Buy
487,869
+14,884
+3% +$90.5K ﹤0.01% 3197
2026
Q1 		$3.63M Sell
472,985
-79,235
-14% -$735K ﹤0.01% 2635
2025
Q4 		$6.25M Sell
552,220
-16,102
-3% -$164K ﹤0.01% 2343
2025
Q3 		$5.23M Sell
568,322
-43,214
-7% -$313K ﹤0.01% 2473
2025
Q2 		$4.21M Sell
611,536
-29,411
-5% -$157K ﹤0.01% 2558
2025
Q1 		$1.85M Sell
640,947
-69,374
-10% -$255K ﹤0.01% 2966
2024
Q4 		$3.34M Buy
710,321
+142,578
+25% +$526K ﹤0.01% 2749
2024
Q3 		$2.03M Buy
567,743
+400,849
+240% +$2.97M ﹤0.01% 2995
2024
Q2 		$1.03M Buy
166,894
+30,461
+22% +$231K ﹤0.01% 3236
2024
Q1 		$1.29M Sell
136,433
-8,532
-6% -$76.2K ﹤0.01% 3197
2023
Q4 		$979K Buy
144,965
+1,984
+1% +$8.8K ﹤0.01% 3326
2023
Q3 		$635K Sell
142,981
-446
-0.3% -$1.95K ﹤0.01% 3446
2023
Q2 		$473K Sell
143,427
-308,525
-68% -$906K ﹤0.01% 3556
2023
Q1 		$1.29M Buy
451,952
+61,476
+16% +$551K ﹤0.01% 3128
2022
Q4 		$2.84M Buy
390,476
+79,183
+25% +$516K ﹤0.01% 2807
2022
Q3 		$2.52M Buy
311,293
+2,999
+1% +$21.5K ﹤0.01% 2891
2022
Q2 		$1.51M Buy
308,294
+51,368
+20% +$502K ﹤0.01% 3203
2022
Q1 		$6.08M Sell
256,926
-6,147
-2% -$87K ﹤0.01% 2468
2021
Q4 		$4.65M Buy
263,073
+5,201
+2% +$103K ﹤0.01% 2722
2021
Q3 		$7.28M Buy
257,872
+40,161
+18% +$761K ﹤0.01% 2498
2021
Q2 		$2.28M Buy
217,711
+20,503
+10% +$207K ﹤0.01% 3295
2021
Q1 		$2.32M Buy
197,208
+7,199
+4% +$89K ﹤0.01% 3157
2020
Q4 		$2.23M Buy
190,009
+11,840
+7% +$134K ﹤0.01% 3148
2020
Q3 		$1.41M Buy
178,169
+10,696
+6% +$129K ﹤0.01% 3223
2020
Q2 		$3.06M Buy
167,473
+33,188
+25% +$523K ﹤0.01% 2806
2020
Q1 		$1.6M Buy
134,285
+83,233
+163% +$1.33M ﹤0.01% 2981
2019
Q4 		$849K Sell
51,052
-2,159
-4% -$20.6K ﹤0.01% 3442
2019
Q3 		$353K Buy
+53,211
New +$589K ﹤0.01% 3622

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust's FULC Position: Q2 2026 in Review

Northern Trust increased its Fulcrum Therapeutics (FULC) stake by 3.1% in Q2 2026, buying an estimated $90.5K and bringing the position to 487,869 shares worth $1.79M. The position accounts for ﹤0.01% of the portfolio, ranked #3197.

Northern Trust first reported a position in FULC in Q3 2019 and has held it in 28 quarters since. The position peaked at $7.28M in Q3 2021. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Northern Trust held 487,869 shares of Fulcrum Therapeutics worth $1.79M as of Q2 2026.
  • Northern Trust bought 14,884 Fulcrum Therapeutics shares in Q2 2026, an estimated $90.5K.
  • Fulcrum Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3197 holding.
  • Northern Trust first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • Northern Trust's Fulcrum Therapeutics position peaked at $7.28M in Q3 2021.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.